Treating Transitional Age Youth with Clozapine-Presentation Slides

Presentation Slides

Pdf Summary

This document is a summary of a presentation on the topic of treating transitional age youth with clozapine, a medication used to treat serious mental illnesses. The presentation is part of an APA and SAMHSA (Substance Abuse and Mental Health Services Administration) initiative called the Clinical Support System for Serious Mental Illness (CSS-SMI). The initiative is funded by SAMHSA and implemented by the American Psychiatric Association (APA).<br /><br />The presentation discusses the use of clozapine in treating transitional age youth, which includes both adolescents and young adults. It compares and contrasts the treatment of clozapine in transitional age youth and adults, justifies the off-label use of clozapine in treating various mental health conditions in youth, and discusses the development of an informed consent process for parents and caregivers.<br /><br />The document provides information on the faculty presenting the material, their credentials, and any disclosures of conflicts of interest. It also includes learning objectives for participants to achieve by the end of the presentation.<br /><br />The presentation covers various aspects of treating transitional age youth with clozapine. It discusses the FDA-registered indications for clozapine, the evidence supporting its off-label use in youth, the risks associated with its use, and risk mitigation and management of side effects. The evidence for using clozapine to treat treatment-resistant schizophrenia, first episode psychosis, suicidality, bipolar I disorder, and aggression in youth is presented.<br /><br />The document provides a bibliography of relevant studies and sources that were referenced in the presentation. It also includes information on getting started with clozapine treatment, including titration protocols and monitoring guidelines. The presentation concludes with information on optimizing treatment and maintaining remission.<br /><br />The document ends with a thank you message and an invitation to submit questions.

Keywords

transitional age youth

clozapine

serious mental illnesses

off-label use

informed consent process

FDA-registered indications

risk mitigation

treatment-resistant schizophrenia

first episode psychosis

suicidality